Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
6
×
boston blog main
boston top stories
life sciences
national blog main
clinical trials
fda
alnylam pharmaceuticals
rna interference
biotech
drugs
national top stories
patisiran
alexion pharmaceuticals
aminolevulinic acid
deals
givosiran
hereditary transthyretin amyloidosis
onpattro
paul matteis
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
amyotrophic lateral sclerosis (als)
andrew fire
autoimmune disorders
boehringer ingelheim
complement system
craig mello
crispr
cystic fibrosis
cystic fibrosis foundation
dicerna pharamceuticals
generalized myasthenia gravis
gilead sciences
hepatitis b
hepatitis b virus
hepatitis c
What
pharmaceuticals
6
×
drug
alnylam
medicine
medicines
rnai
disease
fda
interference
ok
pharma
rna
second
seek
speedy
afternoon
ago
alnylam’s
alternative
approval
approved
autoimmune
candidate
caught
causing
cf
cleared
crisis
cystic
data
deal
developer
dicerna
expensive
eye
far
fibrosis
force
gene
gets
Language
unset
unknown
Current search:
boston
×
pharmaceuticals
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug